Barclays Maintains Overweight on Vir Biotechnology, Lowers Price Target to $41
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang has maintained an Overweight rating on Vir Biotechnology (NASDAQ:VIR) but lowered the price target from $59 to $41.
July 21, 2023 | 9:53 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays has maintained an Overweight rating on Vir Biotechnology but lowered the price target from $59 to $41.
The lowering of the price target by Barclays, a major financial institution, could negatively impact investor sentiment towards Vir Biotechnology, potentially leading to a short-term decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100